AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Autolus Therapeutics shares surge 11.95% after-hours following NICE draft guidance recommending Aucatzyl for B-ALL in the NHS.
ByAinvest
Tuesday, Nov 25, 2025 4:12 pm ET1min read
Autolus Therapeutics surged 11.95% in after-hours trading following the U.K. National Institute for Health and Care Excellence (NICE) recommending its CAR T therapy Aucatzyl (obe-cel) for use in the National Health Service (NHS) to treat relapsed or refractory B-cell acute lymphoblastic leukemia. The approval, based on positive Phase 1 trial results showing high remission rates and a favorable safety profile for obe-cel, enables imminent NHS access and commercialization in England and Wales. Additional momentum came from the company’s presentation of promising clinical data for obe-cel at the American Society of Hematology Annual Meeting, highlighting its potential in hematological and autoimmune diseases. These developments reinforced investor confidence in Autolus’ therapeutic pipeline and market expansion, driving the significant after-hours gain.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet